Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/low-risk-of-viral-infection-after-administration-of-vapor-heated-G8e0Awo062
References (26)
-
Professor and Dean for Faculty and Medical Affairs, Department of Medicine -
(1987)
Detection of factor VlIl and IX inhibitors after first exposure to heat-treated concentrates (letter) -
Other members of the International Investigator Group are -
Professor of Pediatrics, Department of Pediatrics -
J. Eibl, G. Eder, K. Anderle (1988)
ISSUES ASSOCIATED WITH SAFETY TESTING OF BLOOD PRODUCTS IN ENDEMIC AREASBritish Journal of Haematology, 69
-
Carmen Loiselle, Brindha Sitaram, Thomas Hack, Joan Bottorff, Lesley Degner (2008)
Canada and India: an innovative partnership to advance oncology nursing research.Oncology nursing forum, 35 4
-
P. Mannucci, Massimo Colombo (1988)
VIRUCIDAL TREATMENT OF CLOTTING FACTOR CONCENTRATESThe Lancet, 332
-
Longo Longo, Matucci Matucci, Messori Messori, Morfini Morfini, Rossi‐Ferrini Rossi‐Ferrini (1986)
Pharmacokinetic of a new heat‐treated concentrate of factor VIII estimated by model‐independent methodsThromb Res, 42
-
Letter: a more uniform measurement of factor VIII inhibitors
Thromb Diath Haemorrh, 34
-
(1990)
Factor V1II:C inhibitor associated with monoclonal-antibody purified FVIII concentrate (letter) -
(1988)
Acute hepatitis B infection after treatment with heat-inactivated factor VIII concentrate (letter) -
P. Mannucci, A. Zanetti, Massimo Colombo, A. Chistolini, R. Biasi, R. Musso, G. Tamponi (1990)
Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. The Study Group of the Fondazione dell'Emofilia.Thrombosis and haemostasis, 64 2
-
P. Kernoff, C. Lee, P. Karayiannis, H. Thomas (1985)
High risk of non‐A non‐B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulinBritish Journal of Haematology, 60
-
Mannucci Mannucci, Colombo Colombo (1989)
Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and HemostasisThromb Haemost, 61
-
D. Thomas (1988)
REDUCING THE RISK OF VIRUS TRANSMISSION BY BLOOD PRODUCTSBritish Journal of Haematology, 70
-
(1985)
Steam treatment of freeze - dried plasma fractions -
P. Mannucci, M. Colombo (1989)
Revision of the Protocol Recommended for Studies of Safety from Hepatitis of Clotting Factor ConcentratesThrombosis and Haemostasis, 61
-
Doreen Brettler, Peter Levine (1989)
Factor concentrates for treatment of hemophilia: which one to choose?Blood, 73 8
-
M. Fletcher, J. Trowell, J. Craske, K. Pavier, C. Rizza (1983)
Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients.British Medical Journal (Clinical research ed.), 287
-
H. Alter, R. Purcell, J. Shih, J. Melpolder, M. Houghton, Q. Choo, G. Kuo (1989)
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.The New England journal of medicine, 321 22
-
K. Schimpf, P. Mannucci, W. Kreutz, H. Bragkmann, C. Auerswald, Nicola Ciavarella, J. Mößeler, V. Derosa, B. Kraus, Ch. Bruegkmann, G. Mancuso, U. Mittler, F. Haschke, Massimo Morfini (1987)
Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions.The New England journal of medicine, 316 15
-
J. Hanley, A. Lippman‐Hand (1983)
If nothing goes wrong, is everything all right? Interpreting zero numerators.JAMA, 249 13
-
(1988)
Safety of therapeutic products used for hemophilia patients.MMWR. Morbidity and mortality weekly report, 37 29
-
Safety of therapeutic products used for hemophilia patients
Morbid Mortal Weekly Rep, 37
-
Schimpf Schimpf, Mannucci Mannucci, Kreutz Kreutz (1987)
Absence of hepatitis after treatment with a pasteurized factor VIIIN Engl J Med, 316
-
P. Mannucci, A. Zanetti, M. Colombo (1988)
Prospective study of hepatitis after factor VIII concentrate exposed to hot vapourBritish Journal of Haematology, 68
- Publisher
- Wiley
- Copyright
- 1992 AABB
- ISSN
- 0041-1132
- eISSN
- 1537-2995
- DOI
- 10.1046/j.1537-2995.1992.32292180141.x
- Publisher site
- See Article on Publisher Site
Abstract
A multicenter prospective study was carried out to evaluate whether a vapor‐heated factor VIII concentrate transmitted blood‐borne viral infections over a surveillance period of 15 months. Thirty‐five patients with hemophilia and von Willebrand disease who had never received any blood components were treated. Twenty‐eight were analyzed and found not to have non‐A,non‐B hepatitis. Sera from 20 of these 28 patients were also tested for the antibody to the hepatitis C virus. None had sero‐converted during the follow‐up period. None of the patients analyzed developed markers of the hepatitis B virus (n = 17) or the human immunodeficiency virus (n = 31). This vapor‐heated factor VIII concentrate carries a low risk of transmitting hepatitis and human immunodeficiency virus infection.
Journal
Transfusion – Wiley
Published: Feb 1, 1992